肌少症对住院老年2型糖尿病患者远期预后的影响:前瞻性队列研究

Impact of Sarcopenia on Long-term Outcomes in Elderly Inpatients with Type 2 Diabetes: A Prospective Cohort Study

  • 摘要: 目的 分析肌少症对老年 2 型糖尿病(type 2 diabetes mellitus, T2DM)患者远期预后的影响。 方法 连续入选 2017 年 1 月至 2021 年 1 月于北京协和医院老年医学科住院治疗、 年龄≥65 岁的 T2DM 患者。 肌少症的评估采用 2014 年亚洲肌少症工作组(Asian working group of sarcopenia, AWGS)制定的肌少症诊断标准, 同时评估患者的共存疾病情况、功能状态、营养状态及合并老年综合征的情况。 采取门诊随诊和电话随访的方法进行随访,随访内容包括发生重度失能、再住院以及全因死亡情况。 采用 Cox 回归分析合并肌少症对老年 T2DM 住院患者远期预后(重度失能、再住院以及全因死亡) 的影响。 结果 共入选符合纳入和排除标准的老年 T2DM 住院患者 244 例,其中男性 110 例 (45.1%)、 女性 134例(54.9%);年龄 65~93 岁,中位年龄 74 岁。 在 3~ 7 年(中位随访时间 5.6 年)的随访期内, 25.4%(62/244)的患者合并肌少症。 合并肌少症的老年 T2DM 患者发生重度失能、再住院及全因死亡的比例均显著高于非肌少症老年 T2DM 患者(P 均<0.001)。校正性别、年龄、共存疾病程度后, Cox 回归分析显示,合并肌少症是老年 T2DM 患者发生重度失能(HR=4.693, 95%CI: 1.253~17.579,P=0.022)、再住院(HR=1.755, 95%CI: 1.053~2.926, P=0.031)以及全因死亡(HR=2.255, 95%CI: 1.078~4.713, P=0.031)的独立危险因素; 年龄校正的 Charlson共病指数亦是患者全因死亡的危险因素(HR=1.237, 95%CI: 1.046~1.464,P=0.013) 。 结论 老年 T2DM 住院患者合并肌少症的患病率高,合并肌少症显著增加老年 T2DM 患者的远期不良预后。 临床医师应重视对老年 T2DM 患者合并肌少症的筛查与干预,以提高老年 T2DM 患者生活质量,改善老年 T2DM 患者远期预后。

     

    Abstract: Objective To investigate the collective influence of sarcopenia on the extended prognosis of hospitalized elderly individuals with Type 2 Diabetes Mellitus (T2DM). Methods Patients with T2DM aged 65 years and older, who were admitted to the Geriatrics Department of Peking Union Medical College Hospital between January 2017 and January 2021, were consecutively enrolled in the study. The presence of sarcopenia was evaluated based on the diagnostic criteria established by the Asian Working Group for Sarcopenia (AWGS) in 2014. Additionally, assessments were made on the patients' comorbidities, functional status, nutritional status, and geriatric syndromes. Follow-up was conducted through outpatient visits and telephone calls to monitor outcomes such as severe disability, rehospitalization, and all-cause mortality. Cox regression analysis was performed to investigate the impact of concurrent sarcopenia on the long-term prognosis of elderly individuals with T2DM who were hospitalized. Results A total of 244 elderly inpatients with T2DM who met specific criteria were included in the study, comprising 110 males (45.1%) and 134 females (54.9%), with ages ranging from 65 to 93 years and a median age of 74 years. Over a follow-up period of 3 to 7 years (median 5.6 years), sarcopenia was observed in 25.4% (62/244) of patients. Elderly T2DM patients with sarcopenia exhibited significantly higher rates of severe disability, rehospitalization, and all-cause death compared to those without sarcopenia (all P<0.001). Cox regression analysis, adjusting for gender, age, and comorbidities, revealed that sarcopenia was a significant predictor of severe disability (HR=4.693, 95% CI: 1.253-17.579, P=0.022), rehospitalization (HR=1.755, 95% CI: 1.053-2.926, P=0.031), and all-cause death (HR=2.255, 95% CI: 1.078-4.713, P=0.031). Additionally, the age-adjusted Charlson comorbidity index emerged as an independent risk factor for all-cause death (HR=1.237, 95% CI: 1.046-1.464, P=0.013). Conclusions The prevalence of sarcopenia is notably high among hospitalized elderly patients with T2DM, greatly affecting their long-term prognosis. It is imperative for clinicians to prioritize screening and implementing interventions for sarcopenia in elderly T2DM patients to improve their quality of life and overall prognosis.

     

/

返回文章
返回